NCT03248180 (GDR) is a clinical trial in Psychosis, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT03248180?

NCT03248180 is sponsored by National Taiwan University Hospital.

What condition does NCT03248180 study?

NCT03248180 studies Psychosis, Remission.

Is NCT03248180 still recruiting?

NCT03248180 is currently status unknown. Last updated 14 August 2017.

Last reviewed 2017-08-14 · How we verify

NCT03248180: GDR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States

Status unknown Last updated 14 August 2017

What this trial tests

trial in Psychosis in 160 participants. Status unknown.

Timeline

24 July 2017

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	National Taiwan University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	160
Start date	24 July 2017
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across Taiwan

Conditions studied

Psychosis — all drugs for Psychosis →
Remission — all drugs for Remission →

Sponsor

National Taiwan University Hospital

Who can join

Adults 18 to 50, any sex, with Psychosis or Remission. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A 2-year prospective observational study comparing a group of patients in remitted states of psychosis undergoing guided antipsychotic dose reduction to a similar group of patients under maintenance antipsychotic treatment with the main outcome of interest that if the rates of relapse of psychosis between these two groups will be different.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort.
Liu CC, Hsieh MH, Chien YL, Liu CM, et al · · 2023 · cited 20× · PMID 36896797 · DOI 10.1017/s0033291723000429
Dose-tapering trajectories in patients with remitted psychosis undergoing guided antipsychotic reduction to reach minimum effective dose.
Liu CC, Hsieh MH, Chien YL, Liu CM, et al · · 2023 · cited 4× · PMID 37578111 · DOI 10.1192/j.eurpsy.2023.2440
Verification of successful maintenance by serum drug level during a guided antipsychotic reduction to reach minimum effective dose (GARMED) trial.
Liu CI, Liu CM, Chiu HH, Chuang CC, et al · · 2024 · cited 2× · PMID 39324399 · DOI 10.1017/s0033291724002356
Successful antipsychotic dose tapering leading to better cognition in patients with remitted psychosis: Results of Guided Antipsychotic Reduction to Reach Minimum Effective Dose (GARMED) trial.
Liu CI, Liu CM, Hsieh MH, Lin YT, et al · · 2025 · PMID 40862646 · DOI 10.1017/s0033291725101591

Verify or expand the search:

Other recruiting trials for Psychosis

Currently open trials in the same condition.

NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
NCT07196462 — Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia · NA · recruiting
NCT07364825 — Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care · NA · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03248180 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 14 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03248180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing